Roy Buchanan
Stock Analyst at JMP Securities
(1.09)
# 2,744
Out of 4,502 analysts
34
Total ratings
36.36%
Success rate
-19.45%
Average return
Main Sectors:
Top Industries:
11 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CVAC CureVac | Reiterates: Market Outperform | $18 | $3.64 | +394.51% | 5 | Jul 3, 2024 | |
| GRTS Gritstone bio | Reiterates: Market Outperform | $5 | $0.66 | +661.27% | 3 | Jun 14, 2024 | |
| ENTA Enanta Pharmaceuticals | Maintains: Market Outperform | $23 → $22 | $15.33 | +43.51% | 7 | May 7, 2024 | |
| ABUS Arbutus Biopharma | Reiterates: Market Outperform | $4 | $3.92 | +2.04% | 4 | Apr 4, 2024 | |
| ANTX AN2 Therapeutics | Upgrades: Market Outperform | $6 | $2.64 | +127.27% | 3 | Apr 2, 2024 | |
| INO Inovio Pharmaceuticals | Initiates: Market Outperform | $12 | $10.95 | +9.59% | 1 | Jan 4, 2024 | |
| DVAX Dynavax Technologies | Maintains: Market Outperform | $25 → $27 | $11.48 | +135.19% | 5 | Nov 3, 2023 | |
| ESPR Esperion Therapeutics | Reiterates: Market Outperform | $15 | $2.43 | +517.28% | 1 | Mar 6, 2023 | |
| ARGX argenx SE | Maintains: Market Outperform | $443 → $448 | $486.33 | -7.88% | 2 | Mar 3, 2023 | |
| CRMD CorMedix | Maintains: Market Perform | $14 → $16 | $4.71 | +239.70% | 1 | Mar 1, 2023 | |
| IBIO iBio, Inc. | Downgrades: Market Perform | n/a | $2.22 | - | 2 | Feb 16, 2023 |
CureVac
Jul 3, 2024
Reiterates: Market Outperform
Price Target: $18
Current: $3.64
Upside: +394.51%
Gritstone bio
Jun 14, 2024
Reiterates: Market Outperform
Price Target: $5
Current: $0.66
Upside: +661.27%
Enanta Pharmaceuticals
May 7, 2024
Maintains: Market Outperform
Price Target: $23 → $22
Current: $15.33
Upside: +43.51%
Arbutus Biopharma
Apr 4, 2024
Reiterates: Market Outperform
Price Target: $4
Current: $3.92
Upside: +2.04%
AN2 Therapeutics
Apr 2, 2024
Upgrades: Market Outperform
Price Target: $6
Current: $2.64
Upside: +127.27%
Inovio Pharmaceuticals
Jan 4, 2024
Initiates: Market Outperform
Price Target: $12
Current: $10.95
Upside: +9.59%
Dynavax Technologies
Nov 3, 2023
Maintains: Market Outperform
Price Target: $25 → $27
Current: $11.48
Upside: +135.19%
Esperion Therapeutics
Mar 6, 2023
Reiterates: Market Outperform
Price Target: $15
Current: $2.43
Upside: +517.28%
argenx SE
Mar 3, 2023
Maintains: Market Outperform
Price Target: $443 → $448
Current: $486.33
Upside: -7.88%
CorMedix
Mar 1, 2023
Maintains: Market Perform
Price Target: $14 → $16
Current: $4.71
Upside: +239.70%
iBio, Inc.
Feb 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $2.22
Upside: -